Study of Cilostazol and Probucol to Assess Their Effects on Atherosclerosis Related Biomarker

PHASE4CompletedINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

October 31, 2008

Primary Completion Date

August 31, 2009

Study Completion Date

March 31, 2010

Conditions
Type 2 Diabetes MellitusArteriosclerosis Obliterans
Interventions
DRUG

Cilostazol

From 50mg, Bid, PO after breakfast and dinner. After 1-week of administration, if no significant study drug related discomfort, the dose can increase to 100mg, Bid, PO. Otherwise, remain at the 50 mg level.

DRUG

Probucol

250 mg Bid, PO after breakfast and dinner.

DRUG

Cilostazol+Probucol

OTHER

Control Group

Routine treatment

Trial Locations (1)

Unknown

Peking University First Hospital, Beijing

All Listed Sponsors
lead

Otsuka Beijing Research Institute

INDUSTRY